Prosensa Treats First Patient in Phase III Trial of DMD Drug
By Nuala Moran
Thursday, January 27, 2011
LONDON Prosensa NV announced that the first patient has started treatment in the Phase III trial of its lead antisense product for treating the progressive, inherited muscle-wasting disease Duchenne's muscular dystrophy (DMD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.